XENEN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Balance Sheet & RunwayA strong, low‑leverage balance sheet with roughly $1.3B in cash provides multi‑year funding to complete pivotal filings, scale commercial launch preparations and advance multiple programs without immediate financing. This materially lowers solvency risk and supports strategic optionality through 2029.
Pivotal XTOL‑2 Efficacy And Durable OLE ResultsRobust pivotal results and long‑term open‑label seizure‑freedom signals create durable clinical differentiation that strengthens regulatory filing prospects and prescriber confidence. Sustained efficacy and responder signals improve the odds of favorable labeling, formulary positioning and long‑term adoption post‑approval.
Broader Pipeline And HCP EngagementA diversified late‑stage and emerging pipeline reduces single‑asset binary risk and extends potential revenue streams beyond one product. Strong clinician engagement and a substantial safety database support uptake and payer discussions, enhancing long‑term franchise scalability if approvals succeed.
Bears Say
Sustained Cash BurnPersistent high negative operating and free cash flow creates ongoing funding dependence. Even with current cash, continued burn requires careful capital planning; setbacks or slower revenue ramp would force additional financing, increasing dilution risk and constraining long‑term investment flexibility.
Pre‑commercial Profile And Widening LossesZero trailing revenue and materially widening operating losses underscore that profitability is contingent on successful approvals and commercial execution. The business must convert clinical success into sustainable sales, otherwise returns remain negative and shareholder value is dependent on future execution.
Commercial Execution And Payer Access RiskLong‑term value hinges on effective sales force build, payer negotiations and real‑world uptake. Weaknesses in launch execution or limited coverage could materially delay revenues or necessitate price concessions, making payer/commercial execution a persistent structural risk even after approval.
XENEN FAQ
What was Xenon Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Xenon Pharmaceuticals’s market cap?
Currently, no data Available
When is Xenon Pharmaceuticals’s upcoming earnings report date?
Xenon Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 16 days.
How were Xenon Pharmaceuticals’s earnings last quarter?
Xenon Pharmaceuticals released its earnings results on May 07, 2026. The company reported -$20.398 earnings per share for the quarter, beating the consensus estimate of -$20.555 by $0.157.
Is Xenon Pharmaceuticals overvalued?
According to Wall Street analysts Xenon Pharmaceuticals’s price is currently Undervalued.
Does Xenon Pharmaceuticals pay dividends?
Xenon Pharmaceuticals does not currently pay dividends.
What is Xenon Pharmaceuticals’s EPS estimate?
Xenon Pharmaceuticals’s EPS estimate is -19.89.
How many shares outstanding does Xenon Pharmaceuticals have?
Currently, no data Available
What happened to Xenon Pharmaceuticals’s price movement after its last earnings report?
Xenon Pharmaceuticals reported an EPS of -$20.398 in its last earnings report, beating expectations of -$20.555. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Xenon Pharmaceuticals?
Currently, no hedge funds are holding shares in MX:XENEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.58%
Trailing 12-Months
Company Description
Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
XENEN Earnings Call
Q1 2026
0:00 / 0:00
XENEN Stock 12 Month Forecast
Average Price Target
$1,326.56